ConductScience.org, home

Comparison · NCT04924036-sae

Glycopyrronium Cloths vs Placebo: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Glycopyrronium Cloths vs Placebo: serious adverse events. Trial comparisons, record NCT04924036-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04924036-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.07690.01370.333wilson
Risk in group 2000.228wilson
Risk difference, group 1 minus group 20.0769-0.160.333newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harm, for one more participant with a serious adverse event on Glycopyrronium Cloths than on Placebo13from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Glycopyrronium Cloths
Participants Randomized to glycopyrronium cloths.~glycopyrronium cloths: Qbrexza is an anticholinergic indicated for topical treatment of axillary hyperhidrosis in adults and pediatric patients 9 years of age and older
113EG000
Group 2PlaceboParticipants that are randomized to placebo cloths.~Placebo: Placebo for this study are cloths that look like the qbrexza cloths but do not have any active ingredient.013EG001

Harm

What it counts
Total, serious adverse events
Time frame
17 months

Source ClinicalTrials.gov

Trial

Title
Qbrexza Cloths for Hyperhidrosis of Amputation Sites
NCT number
NCT04924036
Phases
PHASE2
Conditions
Amputation, Hyperhidrosis
Interventions
glycopyrronium cloths, Placebo
Lead sponsor
University of Utah
Results first posted
2026-01-22

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04924036-sae